CliffBio
biologic

Opdivo

nivolumab

Loss of exclusivityOctober 2029projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →See this company's full patent-cliff portfolio

Drug detail

Brand nameOpdivo
Active ingredientnivolumab
Strength240MG/24ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2017
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.